During the last session, Edwards Lifesciences Corp (NYSE:EW)’s traded shares were 2.56 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $92.70, reflecting an intraday gain of 1.64% or $1.5. The 52-week high for the EW share is $96.12, that puts it down -3.69 from that peak though still a striking 34.66% gain since the share price plummeted to a 52-week low of $60.57. The company’s market capitalization is $55.74B, and the average intraday trading volume over the past 10 days was 3.13 million shares, and the average trade volume was 4.07 million shares over the past three months.
Edwards Lifesciences Corp (NYSE:EW) trade information
Edwards Lifesciences Corp (EW) registered a 1.64% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.64% in intraday trading to $92.70, hitting a weekly high. The stock’s 5-day price performance is -2.99%, and it has moved by 4.95% in 30 days. Based on these gigs, the overall price performance for the year is 11.42%. The short interest in Edwards Lifesciences Corp (NYSE:EW) is 10.45 million shares and it means that shorts have 2.57 day(s) to cover.
Edwards Lifesciences Corp (EW) estimates and forecasts
Statistics show that Edwards Lifesciences Corp has underperformed its competitors in share price, compared to the industry in which it operates. Edwards Lifesciences Corp (EW) shares have gone up 30.07% during the last six months, with a year-to-date growth rate less than the industry average at 9.96% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 3.20% this quarter and then jump 6.10% in the quarter after that. In the rating firms’ projections, revenue will increase 8.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.57 billion as predicted by 23 analyst(s). Meanwhile, a consensus of 23 analyst(s) estimates revenue growth to $1.64 billion by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.46 billion and $1.5 billion respectively. In this case, analysts expect current quarter sales to grow by 7.90% and then jump by 9.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.35%. While earnings are projected to return 9.78% in 2024, the next five years will return 9.34% per annum.
EW Dividends
Edwards Lifesciences Corp is due to release its next quarterly earnings between April 24 and April 29. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Edwards Lifesciences Corp (NYSE:EW)’s Major holders
Edwards Lifesciences Corp insiders own 0.89% of total outstanding shares while institutional holders control 84.05%, with the float percentage being 84.80%. Vanguard Group Inc is the largest shareholder of the company, while 1,783 institutions own stock in it. As of Jun 29, 2023, the company held over 51.31 million shares (or 8.44% of all shares), a total value of $4.84 billion in shares.
The next largest institutional holding, with 50.81 million shares, is of Blackrock Inc.’s that is approximately 8.36% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $4.79 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Edwards Lifesciences Corp (EW) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 18.92 million shares. This amounts to just over 3.11 percent of the company’s overall shares, with a $1.78 billion market value. The same data shows that the other fund manager holds slightly less at 14.43 million, or about 2.37% of the stock, which is worth about $1.36 billion.
